Novartis India Limited (NOVARTIND.BO)
INR 789.4
(0.41%)
INR 789.4
(0.41%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 448.6 Million INR | -18.02% |
| 2022 | 547.2 Million INR | -4.12% |
| 2021 | 570.7 Million INR | 19.02% |
| 2020 | 479.5 Million INR | -18.29% |
| 2019 | 586.8 Million INR | -3.02% |
| 2018 | 605.1 Million INR | 6.98% |
| 2017 | 565.6 Million INR | -35.37% |
| 2016 | 875.2 Million INR | 20.88% |
| 2015 | 724 Million INR | 9.5% |
| 2014 | 661.2 Million INR | -36.17% |
| 2013 | 1.03 Billion INR | -5.96% |
| 2012 | 1.1 Billion INR | 39.41% |
| 2011 | 790.1 Million INR | 47.35% |
| 2010 | 536.2 Million INR | 4.37% |
| 2009 | 513.75 Million INR | 2.54% |
| 2008 | 501.02 Million INR | -25.95% |
| 2007 | 676.56 Million INR | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 335.8 Million INR | 0.0% |
| 2024 Q1 | - INR | -100.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 415.6 Million INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | 448.6 Million INR | 0.0% |
| 2023 FY | 448.6 Million INR | -18.02% |
| 2022 Q2 | 438.9 Million INR | 0.0% |
| 2022 FY | 547.2 Million INR | -4.12% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q4 | 547.2 Million INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2021 Q4 | 570.7 Million INR | 0.0% |
| 2021 Q2 | 467.1 Million INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 570.7 Million INR | 19.02% |
| 2021 Q3 | - INR | -100.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 FY | 479.5 Million INR | -18.29% |
| 2020 Q2 | 643.1 Million INR | 0.0% |
| 2020 Q4 | 479.5 Million INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 FY | 586.8 Million INR | -3.02% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q2 | 654.4 Million INR | 0.0% |
| 2019 Q4 | 586.8 Million INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q2 | 572.2 Million INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 FY | 605.1 Million INR | 6.98% |
| 2018 Q4 | 605.1 Million INR | 0.0% |
| 2017 Q4 | 565.6 Million INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 FY | 565.6 Million INR | -35.37% |
| 2017 Q1 | - INR | -100.0% |
| 2017 Q2 | 697.4 Million INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2016 Q4 | 875.2 Million INR | 0.0% |
| 2016 Q2 | 883.8 Million INR | 0.0% |
| 2016 FY | 875.2 Million INR | 20.88% |
| 2016 Q3 | - INR | -100.0% |
| 2015 Q4 | 724 Million INR | 0.0% |
| 2015 FY | 724 Million INR | 9.5% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q2 | 929.3 Million INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2014 Q1 | - INR | -100.0% |
| 2014 FY | 661.2 Million INR | -36.17% |
| 2014 Q4 | 661.2 Million INR | 0.0% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q2 | 1.01 Billion INR | 0.0% |
| 2013 Q2 | 993.7 Million INR | 0.0% |
| 2013 Q4 | 1.03 Billion INR | 0.0% |
| 2013 FY | 1.03 Billion INR | -5.96% |
| 2013 Q3 | - INR | -100.0% |
| 2013 Q1 | - INR | -100.0% |
| 2012 FY | 1.1 Billion INR | 39.41% |
| 2012 Q4 | 1.1 Billion INR | 0.0% |
| 2012 Q2 | 921.4 Million INR | 0.0% |
| 2012 Q3 | - INR | -100.0% |
| 2011 Q4 | 790.1 Million INR | 0.0% |
| 2011 FY | 790.1 Million INR | 47.35% |
| 2010 FY | 536.2 Million INR | 4.37% |
| 2009 FY | 513.75 Million INR | 2.54% |
| 2008 FY | 501.02 Million INR | -25.95% |
| 2007 FY | 676.56 Million INR | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 16.43 Billion INR | 97.271% |
| Aurobindo Pharma Limited | 98.08 Billion INR | 99.543% |
| Glenmark Life Sciences Limited | 6.66 Billion INR | 93.27% |
| Granules India Limited | 13 Billion INR | 96.551% |
| Indoco Remedies Limited | 3.53 Billion INR | 87.294% |
| Achyut Healthcare Limited | 568 Thousand INR | -78878.873% |
| Ajanta Pharma Limited | 8.28 Billion INR | 94.584% |
| Alkem Laboratories Limited | 26.61 Billion INR | 98.314% |
| Alpa Laboratories Limited | 136.65 Million INR | -228.277% |
| Brooks Laboratories Limited | 96.1 Million INR | -366.767% |
| AstraZeneca Pharma India Limited | 2.27 Billion INR | 80.314% |
| Bajaj HealthCare Limited | 1.44 Billion INR | 68.855% |
| Bliss GVS Pharma Limited | 1.18 Billion INR | 62.127% |
| Dr. Reddy's Laboratories Limited | 63.55 Billion INR | 99.294% |
| Eris Lifesciences Limited | 1.89 Billion INR | 76.269% |
| FDC Limited | 3.88 Billion INR | 88.465% |
| Glenmark Pharmaceuticals Limited | 25.13 Billion INR | 98.215% |
| Gufic Biosciences Limited | 2 Billion INR | 77.624% |
| Ind-Swift Laboratories Limited | 104.57 Million INR | -328.966% |
| Ipca Laboratories Limited | 24.71 Billion INR | 98.185% |
| Jagsonpal Pharmaceuticals Limited | 149.97 Million INR | -199.126% |
| Krebs Biochemicals & Industries Limited | 97.96 Million INR | -357.923% |
| Lasa Supergenerics Limited | 190.43 Million INR | -135.567% |
| Laurus Labs Limited | 18.45 Billion INR | 97.569% |
| Lupin Limited | 49.53 Billion INR | 99.094% |
| Mankind Pharma Limited | 15.53 Billion INR | 97.112% |
| Medicamen Biotech Limited | 593.75 Million INR | 24.447% |
| Medico Remedies Limited | 163.37 Million INR | -174.588% |
| Megasoft Limited | - INR | -Infinity% |
| NATCO Pharma Limited | 7 Billion INR | 93.596% |
| Piramal Pharma Limited | 21.75 Billion INR | 97.938% |
| RPG Life Sciences Limited | 1.01 Billion INR | 55.584% |
| Sigachi Industries Limited | 707.2 Million INR | 36.567% |
| Sun Pharmaceutical Industries Limited | 98.68 Billion INR | 99.545% |
| Suven Pharmaceuticals Limited | 2.31 Billion INR | 80.597% |
| Syncom Formulations (India) Limited | 210.81 Million INR | -112.793% |
| Unichem Laboratories Limited | 7.04 Billion INR | 93.634% |
| Wanbury Limited | 360.23 Million INR | -24.531% |
| Windlas Biotech Limited | 621.89 Million INR | 27.865% |
| ZIM Laboratories Limited | 812.62 Million INR | 44.796% |
| Zydus Lifesciences Limited | 34.41 Billion INR | 98.697% |
| Sun Pharma Advanced Research Company Limited | - INR | -Infinity% |
| Divi's Laboratories Limited | 31.84 Billion INR | 98.591% |
| Hester Biosciences Limited | 755.81 Million INR | 40.646% |
| Procter & Gamble Health Limited | 1.09 Billion INR | 58.886% |
| Amrutanjan Health Care Limited | 289.04 Million INR | -55.2% |
| Bal Pharma Limited | 878.11 Million INR | 48.913% |
| Strides Pharma Science Limited | 11.26 Billion INR | 96.017% |
| Venus Remedies Limited | 1.21 Billion INR | 63.136% |
| Aarti Pharmalabs Limited | 6.42 Billion INR | 93.022% |
| Nectar Lifesciences Limited | 7.09 Billion INR | 93.674% |
| Shilpa Medicare Limited | 3.44 Billion INR | 86.994% |
| Aarti Drugs Limited | 4.85 Billion INR | 90.767% |
| IOL Chemicals and Pharmaceuticals Limited | 4.24 Billion INR | 89.441% |
| Suven Life Sciences Limited | 7.08 Million INR | -6231.687% |
| Ind-Swift Limited | 640.91 Million INR | 30.006% |
| Valiant Laboratories Limited | 100.15 Million INR | -347.91% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.02 Billion INR | 91.073% |
| Solara Active Pharma Sciences Limited | 3.59 Billion INR | 87.528% |
| Themis Medicare Limited | 705.74 Million INR | 36.436% |
| Hikal Limited | 3.03 Billion INR | 85.23% |
| Torrent Pharmaceuticals Limited | 22.79 Billion INR | 98.032% |
| Sequent Scientific Limited | 3.46 Billion INR | 87.043% |
| Wockhardt Limited | 6.4 Billion INR | 92.991% |
| Jubilant Pharmova Limited | 12.89 Billion INR | 96.521% |
| Biofil Chemicals and Pharmaceuticals Limited | 25.49 Million INR | -1659.423% |
| Neuland Laboratories Limited | 3.5 Billion INR | 87.198% |
| Morepen Laboratories Limited | 2.48 Billion INR | 81.955% |
| Kilitch Drugs (India) Limited | 39.88 Million INR | -1024.875% |
| Mangalam Drugs & Organics Limited | 1.23 Billion INR | 63.717% |